• 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 2
    Shah JP, Gil Z. Current concepts in management of oral cancer-surgery. Oral Oncol. 2009; 45: 394-401.
  • 3
    Linsen SS, Martini M, Stark H. Long-term results of endosteal implants following radical oral cancer surgery with and without adjuvant radiation therapy. Clin Implant Dent Relat Res. 2012; 14: 250-258.
  • 4
    Hartl DM, Ferlito A, Silver CE, et al. Minimally invasive techniques for head and neck malignancies: current indications, outcomes and future directions. Eur Arch Otorhinolaryngol. 2011; 268: 1249-1257.
  • 5
    Genden EM, Kotz T, Tong CC, et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope. 2011; 121: 1668-1674.
  • 6
    O'Malley BW Jr, Weinstein GS, Snyder W, Hockstein NG. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope. 2006; 116: 1465-1472.
  • 7
    Weinstein GS, O'Malley BW Jr, Snyder W, Sherman E, Quon H. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg. 2007; 133: 1220-1226.
  • 8
    Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992; 25: 231-241.
  • 9
    Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck: the University of Florida experience. Head Neck. 1993; 15: 87-96.
  • 10
    Garden AS, Morrison WH, Ang KK, Peters LJ. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. Int J Radiat Oncol Biol Phys. 1995; 31: 493-502.
  • 11
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000; 48: 7-16.
  • 12
    Altman MB, Chmura SJ, Deasy JO, Roeske JC. Optimization of the temporal pattern of radiation: an IMRT based study. Int J Radiat Oncol Biol Phys. 2006; 66: 898-905.
  • 13
    Yang J, Fowler JF, Lamond JP, Lanciano R, Feng J, Brady LW. Red shell: defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010; 77: 903-909.
  • 14
    Krayenbuehl J, Davis JB, Ciernik IF. Dynamic intensity-modulated non-coplanar arc radiotherapy (INCA) for head and neck cancer. Radiother Oncol. 2006; 81: 151-157.
  • 15
    Korreman S, Medin J, Kjaer-Kristoffersen F. Dosimetric verification of RapidArc treatment delivery. Acta Oncol. 2009; 48: 185-191.
  • 16
    Vanetti E, Clivio A, Nicolini G, et al. Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT. Radiother Oncol. 2009; 92: 111-117.
  • 17
    Doornaert P, Verbakel WF, Bieker M, Slotman BJ, Senan S. RapidArc planning and delivery in patients with locally advanced head-and-neck cancer undergoing chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011; 79: 429-435.
  • 18
    van Vulpen M, Field C, Raaijmakers CP, et al. Comparing step-and-shoot IMRT with dynamic helical tomotherapy IMRT plans for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005; 62: 1535-1539.
  • 19
    Fiorino C, Dell'Oca I, Pierelli A, et al. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol. 2006; 78: 276-282.
  • 20
    Sheng K, Molloy JA, Larner JM, Read PW. A dosimetric comparison of non-coplanar IMRT versus helical tomotherapy for nasal cavity and paranasal sinus cancer. Radiother Oncol. 2007; 82: 174-178.
  • 21
    Chen AM, Jennelle RL, Sreeraman R, et al. Initial clinical experience with helical tomotherapy for head and neck cancer. Head Neck. 2009; 31: 1571-1578.
  • 22
    Kodaira T, Tomita N, Tachibana H, et al. Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys. 2009; 73: 1129-1134.
  • 23
    Farrag A, Voordeckers M, Tournel K, De Coninck P, Storme G. Pattern of failure after helical tomotherapy in head and neck cancer. Strahlenther Onkol. 2010; 186: 511-516.
  • 24
    Moon SH, Jung YS, Ryu JS, et al. Outcomes of postoperative simultaneous modulated accelerated radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81: 140-149.
  • 25
    Murthy V, Master Z, Gupta T, et al. Helical tomotherapy for head and neck squamous cell carcinoma: dosimetric comparison with linear accelerator-based step-and-shoot IMRT. J Cancer Res Ther. 2010; 6: 194-198.
  • 26
    Voordeckers M, Everaert H, Tournel K, et al. Longitudinal assessment of parotid function in patients receiving tomotherapy for head-and-neck cancer. Strahlenther Onkol. 2008; 184: 400-405.
  • 27
    Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009; 75: 1493-1500.
  • 28
    Roh KW, Jang JS, Kim MS, et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2009; 74: 1348-1355.
  • 29
    Rwigema JC, Heron DE, Ferris RL, Gibson M, Quinn A, Yang Y, Ozhasoglu C, Burton S. Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol. 2010; 33: 286-293.
  • 30
    Siddiqui F, Patel M, Khan M, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2009; 74: 1047-1053.
  • 31
    Truong MT, Grillone G, Tschoe C, Chin L, Kachnic LA, Jalisi S. Emerging applications of stereotactic radiotherapy in head and neck cancer. Neurosurg Focus. 2009; 27: E11.
  • 32
    Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, Cox JD, Chang JY. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010; 77: 357-366.
  • 33
    Zhang X, Penagaricano J, Moros EG, Corry PM, Yan Y, Ratanatharathorn V. Dosimetric comparison of helical tomotherapy and linac-IMRT treatment plans for head and neck cancer patients. Med Dosim. 2010; 35: 264-268.
  • 34
    Kawaguchi K, Sato K, Horie A, et al. Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma. Radiat Oncol. 2010; 5: 51.
  • 35
    Cengiz M, Ozyigit G, Yazici G, et al. Salvage reirradiation with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2011; 81: 104-109.
  • 36
    Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011; 11: 239-253.
  • 37
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
  • 38
    Ang KK, Zhang QE, Rosehthal II. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation and cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinoma. J Clin Oncol. 2011; 29: Suppl. Abstr. 5500.
  • 39
    Ballen KK, King RJ, Chitphakdithai P, et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008; 14( suppl 9): 2-7.
  • 40
    McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001; 97: 3390-3400.
  • 41
    Levine JE, Uberti JP, Ayash L, et al. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biol Blood Marrow Transplant. 2003; 9: 189-197.
  • 42
    Murphy BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol. 2007; 5( 9 suppl 4): 13-21.
  • 43
    Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008; 6( suppl 1): S1-S21; quiz S22-S24.
  • 44
    Boers-Doets CB, Epstein JB, Raber-Durlacher JE, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist. 2012; 17: 135-144.
  • 45
    de Oliveira MA, Martins E, Martins F, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol. 2011; 47: 998-1003.
  • 46
    Multinational Association of Supportive Care in Cancer (MASCC). Mucositis Guidelines. Accessed July 22, 2012.
  • 47
    Keefe DM, Schubert MM, Elting LS, et al; Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109: 820-831.
  • 48
    Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007; 67: 2045-2075.
  • 49
    Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs. 2010; 70: 167-179.
  • 50
    Chang JE, Kahl BS. Current status of targeted therapies for mantle cell lymphoma. Drugs. 2011; 71: 2307-2326.
  • 51
    Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011; 47: 441-448.
  • 52
    Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res. 2006; 85: 690-700.
  • 53
    Sonis ST. A biological approach to mucositis. J Support Oncol. 2004; 2: 21-32; discussion 35-36.
  • 54
    Sonis ST, Elting LS, Keefe D, et al; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100( suppl 9): 1995-2025.
  • 55
    Posner MR, Haddad RI. Novel agents for the treatment of mucositis. J Support Oncol. 2007; 5( 9 suppl 4): 33-39.
  • 56
    Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006; 106: 329-336.
  • 57
    Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003; 39: 91-100.
  • 58
    Dodd MJ, Miaskowski C, Shiba GH, et al. Risk factors for chemotherapy-induced oral mucositis: dental appliances, oral hygiene, previous oral lesions, and history of smoking. Cancer Invest. 1999; 17: 278-284.
  • 59
    Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis–complicating the treatment of cancer. Neoplasia. 2004; 6: 423-431.
  • 60
    Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am. 2008; 52: 79-109, viii-ix.
  • 61
    World Health Organization. WHO Handbook For Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979.
  • 62
    Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176-181.
  • 63
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346.
  • 64
    Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 1999; 85: 2103-2113.
  • 65
    Bateman E, Keefe D. Patient-reported outcomes in supportive care. Semin Oncol. 2011; 38: 358-361.
  • 66
    Epstein JB, Beaumont JL, Gwede CK, et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer. 2007; 109: 1914-1922.
  • 67
    Kushner JA, Lawrence HP, Shoval I, et al. Development and validation of a Patient-Reported Oral Mucositis Symptom (PROMS) scale. J Can Dent Assoc. 2008; 74: 59.
  • 68
    Murphy BA, Dietrich MS, Wells N, et al. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck. 2010; 32: 26-37.
  • 69
    Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg. 2000; 126: 459-467.
  • 70
    List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer. 1996; 77: 2294-2301.
  • 71
    Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007; 29: 923-931.
  • 72
    Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2011;( 4): CD000978.
  • 73
    Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant. 2001; 27( suppl 2): S3-S11.
  • 74
    Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol. 2004; 22: 1268-1275.
  • 75
    Elad S, Epstein JB, von Bultzingslowen I, Drucker S, Tzach R, Yarom N. Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents. Expert Opin Emerg Drugs. 2011; 16: 183-202.
  • 76
    Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007; 68: 1110-1120.
  • 77
    Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66: 253-262.
  • 78
    Rubenstein EB, Peterson DE, Schubert M, et al; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004; 100( suppl 9): 2026-2046.
  • 79
    Brosky ME. The role of saliva in oral health: strategies for prevention and management of xerostomia. J Support Oncol. 2007; 5: 215-225.
  • 80
    Epstein JB, Scully C. The role of saliva in oral health and the causes and effects of xerostomia. J Can Dent Assoc. 1992; 58: 217-221.
  • 81
    Papas A, Russell D, Singh M, Kent R, Triol C, Winston A. Caries clinical trial of a remineralising toothpaste in radiation patients. Gerodontology. 2008; 25: 76-88.
  • 82
    Duncan GG, Epstein JB, Tu D, et al; National Cancer Institute of Canada Clinical Trials Group. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005; 27: 421-428.
  • 83
    Hopcraft MS, Tan C. Xerostomia: an update for clinicians. Aust Dent J. 2010; 55: 238-244; quiz 353.
  • 84
    Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006; 66: 445-453.
  • 85
    Friedman PK, Isfeld D. Xerostomia: the “invisible” oral health condition. J Mass Dent Soc. 2008; 57: 42-44.
  • 86
    Cassolato SF, Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology. 2003; 20: 64-77.
  • 87
    Baum BJ, Bodner L, Fox PC, Izutsu KT, Pizzo PA, Wright WE. Therapy-induced dysfunction of salivary glands: implications for oral health. Spec Care Dentist. 1985; 5: 274-277.
  • 88
    Lin SC, Jen YM, Chang YC, Lin CC. Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of the xerostomia questionnaire. J Pain Symptom Manage. 2008; 36: 141-148.
  • 89
    Grundmann O, Mitchell GC, Limesand KH. Sensitivity of salivary glands to radiation: from animal models to therapies. J Dent Res. 2009; 88: 894-903.
  • 90
    Limesand KH, Schwertfeger KL, Anderson SM. MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells. Mol Cell Biol. 2006; 26: 8840-8856.
  • 91
    Mandel ID. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc. 1989; 119: 298-304.
  • 92
    Koukourakis MI, Danielidis V. Preventing radiation induced xerostomia. Cancer Treat Rev. 2005; 31: 546-554.
  • 93
    Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia. Head Neck. 2007; 29: 58-63.
  • 94
    Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001; 61: 275-280.
  • 95
    Wagner W, Prott FJ, Schonekas KG. Amifostine: a radioprotector in locally advanced head and neck tumors. Oncol Rep. 1998; 5: 1255-1257.
  • 96
    Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys. 2006; 64: 784-791.
  • 97
    Jha N, Seikaly H, Harris J, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol. 2003; 66: 283-289.
  • 98
    Seikaly H, Jha N, Harris JR, et al. Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg. 2004; 130: 956-961.
  • 99
    Atkinson JC, Baum BJ. Salivary enhancement: current status and future therapies. J Dent Educ. 2001; 65: 1096-1101.
  • 100
    Nagler RM, Nagler A. Salivary gland involvement in graft-versus-host disease: the underlying mechanism and implicated treatment. Isr Med Assoc J. 2004; 6: 167-172.
  • 101
    Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC. Oral graft-versus-host disease. Oral Dis. 2008; 14: 396-412.
  • 102
    Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des. 2009; 15: 1974-1997.
  • 103
    Nagler RM, Nagler A. Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant. 1999; 23: 1007-1011.
  • 104
    Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993; 329: 390-395.
  • 105
    Jha N, Seikaly H, Harris J, et al. Phase III randomized study: oral pilocarpine versus submandibular salivary gland transfer protocol for the management of radiation-induced xerostomia. Head Neck. 2009; 31: 234-243.
  • 106
    Chambers MS, Jones CU, Biel MA, et al. Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. Int J Radiat Oncol Biol Phys. 2007; 69: 1369-1376.
  • 107
    Chambers MS, Posner M, Jones CU, et al. Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 1102-1109.
  • 108
    Epstein JB, Burchell JL, Emerton S, Le ND, Silverman S Jr. A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. Oral Surg Oral Med Oral Pathol. 1994; 77: 610-614.
  • 109
    Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman S Jr. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97: 190-195.
  • 110
    Chainani-Wu N, Gorsky M, Mayer P, Bostrom A, Epstein JB, Silverman S Jr. Assessment of the use of sialogogues in the clinical management of patients with xerostomia. Spec Care Dentist. 2006; 26: 164-170.
  • 111
    Epstein JB, Emerton S, Le ND, Stevenson-Moore P. A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol. 1999; 35: 132-137.
  • 112
    Guneri P, Alpoz E, Epstein JB, Cankaya H, Ates M. In vitro antimicrobial effects of commercially available mouth-wetting agents. Spec Care Dentist. 2011; 31: 123-128.
  • 113
    Sreebny L, Chambers MS, Fleming TJ, Martin JW, Toth BB. Xerostomia: managing a complex condition. Interview by Phillip Bonner. Dent Today. 1997; 16: 66-67, 86-87.
  • 114
    Cooperstein E, Gilbert J, Epstein JB, et al. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck. 2012; 34: 797-804.
  • 115
    Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care. 2007; 52: 859-865.
  • 116
    Epstein JB, Chin EA, Jacobson JJ, Rishiraj B, Le N. The relationships among fluoride, cariogenic oral flora, and salivary flow rate during radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 86: 286-292.
  • 117
    Epstein JB, Rea G, Wong FL, Spinelli J, Stevenson-Moore P. Osteonecrosis: study of the relationship of dental extractions in patients receiving radiotherapy. Head Neck Surg. 1987; 10: 48-54.
  • 118
    Epstein J, van der Meij E, McKenzie M, Wong F, Lepawsky M, Stevenson-Moore P. Postradiation osteonecrosis of the mandible: a long-term follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 83: 657-662.
  • 119
    Hong CH, Napenas JJ, Hodgson BD, et al; Dental Disease Section, Oral Care Study Group, Multi-national Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology(ISOO). A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer. 2010; 18: 1007-1021.
  • 120
    Epstein JB, McBride BC, Stevenson-Moore P, Merilees H, Spinelli J. The efficacy of chlorhexidine gel in reduction of Streptococcus mutans and Lactobacillus species in patients treated with radiation therapy. Oral Surg Oral Med Oral Pathol. 1991; 71: 172-178.
  • 121
    Epstein JB, van der Meij EH, Emerton SM, Le ND, Stevenson-Moore P. Compliance with fluoride gel use in irradiated patients. Spec Care Dentist. 1995; 15: 218-222.
  • 122
    Epstein JB, van der Meij EH, Lunn R, Stevenson-Moore P. Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996; 82: 268-275.
  • 123
    Tani G, Tommasoni S. [Considerations on the changes in dental and periodontal tissues induced by Co 60 radiotherapy]. [Article in Italian]. Riv Ital Stomatol. 1967; 22: 1203-1212.
  • 124
    Epstein JB, Corbett T, Galler C, Stevenson-Moore P. Surgical periodontal treatment in the radiotherapy-treated head and neck cancer patient. Spec Care Dentist. 1994; 14: 182-187.
  • 125
    Marques MA, Dib LL. Periodontal changes in patients undergoing radiotherapy. J Periodontol. 2004; 75: 1178-1187.
  • 126
    Colella G, Vuolo G, Siniscalchi G, Moscariello A, Itro A. Radiotherapy for maxillo-facial hemangiomas in children. Dental and periodontal long term effects. [Article in English, Italian]. Minerva Stomatol. 2005; 54: 509-516.
  • 127
    Epstein JB, Stevenson-Moore P. Periodontal disease and periodontal management in patients with cancer. Oral Oncol. 2001; 37: 613-619.
  • 128
    Epstein JB, Lunn R, Le N, Stevenson-Moore P. Periodontal attachment loss in patients after head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 86: 673-677.
  • 129
    Raber-Durlacher JE, Epstein JB, Raber J, et al. Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer. 2002; 10: 466-473.
  • 130
    Lalla RV, Latortue MC, Hong CH, et al; Fungal Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology(ISOO). A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010; 18: 985-992.
  • 131
    Bensadoun RJ, Patton LL, Lalla RV, Epstein JB. Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011. Support Care Cancer. 2011; 19: 737-744.
  • 132
    Epstein JB, Truelove EL, Hanson-Huggins K, et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer. 2004; 12: 517-525.
  • 133
    Stoopler ET. Oral herpetic infections (HSV 1-8). Dent Clin North Am. 2005; 49: 15-29, vii.
  • 134
    Samonis G, Mantadakis E, Maraki S. Orofacial viral infections in the immunocompromised host. Oncol Rep. 2000; 7: 1389-1394.
  • 135
    Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF. Herpes simplex. Pediatr Rev. 2009; 30: 119-129; quiz 130.
  • 136
    Warkentin DI, Epstein JB, Campbell LM, et al. Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. Ann Pharmacother. 2002; 36: 1525-1531.
  • 137
    Epstein JB, Gorsky M, Hancock P, Peters N, Sherlock CH. The prevalence of herpes simplex virus shedding and infection in the oral cavity of seropositive patients undergoing head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 94: 712-716.
  • 138
    Arduino PG, Porter SR. Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med. 2008; 37: 107-121.
  • 139
    Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010; 51: 197-213.
  • 140
    Aberle SW, Mandl CW, Kunz C, Popow-Kraupp T. Presence of human herpesvirus 6 variants A and B in saliva and peripheral blood mononuclear cells of healthy adults. J Clin Microbiol. 1996; 34: 3223-3225.
  • 141
    Nikkels AF, Pierard GE. [Herpesvirus 6. What attention does it deserve in general practice?]. [Article in French]. Rev Med Liege. 2006; 61: 317-321.
  • 142
    Pereira CM, de Almeida OP, Correa ME, Costa FF, de Souza CA, Barjas-Castro ML. Detection of human herpesvirus 6 in patients with oral chronic graft-vs-host disease following allogeneic progenitor cell transplantation. Oral Dis. 2007; 13: 329-334.
  • 143
    Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev. 1997; 10: 521-567.
  • 144
    Ongradi J, Kovesdi V, Kovats E. [Human herpesvirus 7]. [Article in Hungarian]. Orv Hetil. 2010; 151: 645-651.
  • 145
    Caselli E, Di Luca D. Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7. New Microbiol. 2007; 30: 173-187.
  • 146
    Shiboski CH, Patton LL, Webster-Cyriaque JY, et al; Oral HIV/AIDS Research Alliance, Subcommittee of the AIDS Clinical Trial Group. The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med. 2009; 38: 481-488.
  • 147
    Epstein JB, Sherlock CH, Greenspan JS. Hairy leukoplakia-like lesions following bone-marrow transplantation. AIDS. 1991; 5: 101-102.
  • 148
    Kabani S, Greenspan D, deSouza Y, Greenspan JS, Cataldo E. Oral hairy leukoplakia with extensive oral mucosal involvement. Report of two cases. Oral Surg Oral Med Oral Pathol. 1989; 67: 411-415.
  • 149
    Mendoza N, Diamantis M, Arora A, et al. Mucocutaneous manifestations of Epstein-Barr virus infection. Am J Clin Dermatol. 2008; 9: 295-305.
  • 150
    Mustafa MB, Arduino PG, Porter SR. Varicella zoster virus: review of its management. J Oral Pathol Med. 2009; 38: 673-688.
  • 151
    Ongradi J, Kovesdi V, Medveczky GP. [Human herpesvirus 6]. [Article in Hungarian]. Orv Hetil. 2010; 151: 523-532.
  • 152
    Blanchard P, Hill C, Guihenneuc-Jouyaux C, et al; MACH-NC and MARCH Collaborative Groups. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol. 2011; 64: 985-992.
  • 153
    Peterson DE, Doerr W, Hovan A, et al. Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer. 2010; 18: 1089-1098.
  • 154
    Migliorati CA, Woo SB, Hewson I, et al; Bisphosphonate Osteonecrosis Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer. 2010; 18: 1099-1106.
  • 155
    Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983; 41: 283-288.
  • 156
    Epstein JB, Wong FL, Stevenson-Moore P. Osteoradionecrosis: clinical experience and a proposal for classification. J Oral Maxillofac Surg. 1987; 45: 104-110.
  • 157
    Glanzmann C, Gratz KW. Radionecrosis of the mandibula: a retrospective analysis of the incidence and risk factors. Radiother Oncol. 1995; 36: 94-100.
  • 158
    Gomez DR, Estilo CL, Wolden SL, et al. Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e207-e213.
  • 159
    Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys. 2011; 80: 832-839.
  • 160
    Fritz GW, Gunsolley JC, Abubaker O, Laskin DM. Efficacy of pre- and postirradiation hyperbaric oxygen therapy in the prevention of postextraction osteoradionecrosis: a systematic review. J Oral Maxillofac Surg. 2010; 68: 2653-2660.
  • 161
    Epstein J, van der Meij E, McKenzie M, Wong F, Stevenson-Moore P. Hyperbaric oxygen therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996; 81: 265-266.
  • 162
    Teng MS, Futran ND. Osteoradionecrosis of the mandible. Curr Opin Otolaryngol Head Neck Surg. 2005; 13: 217-221.
  • 163
    Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol. 2011; 7: 34-42.
  • 164
    Epstein MS, Ephros HD, Epstein JB. New osteolytic inhibitors: review of current literature and implications of RANKL inhibitors for oral and maxillofacial surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. In press.
  • 165
    Connelly ST, Schmidt BL. Evaluation of pain in patients with oral squamous cell carcinoma. J Pain. 2004; 5: 505-510.
  • 166
    Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II–clinical perspectives and management. J Dent Res. 2007; 86: 506-518.
  • 167
    Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S. Orofacial pain in cancer: part I–mechanisms. J Dent Res. 2007; 86: 491-505.
  • 168
    Bjordal K, Ahlner-Elmqvist M, Hammerlid E, et al. A prospective study of quality of life in head and neck cancer patients. Part II: longitudinal data. Laryngoscope. 2001; 111: 1440-1452.
  • 169
    Chaplin JM, Morton RP. A prospective, longitudinal study of pain in head and neck cancer patients. Head Neck. 1999; 21: 531-537.
  • 170
    Hodder SC, Edwards MJ, Brickley MR, Shepherd JP. Multiattribute utility assessment of outcomes of treatment for head and neck cancer. Br J Cancer. 1997; 75: 898-902.
  • 171
    Gellrich NC, Schramm A, Bockmann R, Kugler J. Follow-up in patients with oral cancer. J Oral Maxillofac Surg. 2002; 60: 380-386; discussion 387-388.
  • 172
    Hammerlid E, Silander E, Hornestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer–a longitudinal study. Head Neck. 2001; 23: 113-125.
  • 173
    Terrell JE, Welsh DE, Bradford CR, et al. Pain, quality of life, and spinal accessory nerve status after neck dissection. Laryngoscope. 2000; 110: 620-626.
  • 174
    Rogers SN, Lowe D, McNally D, Brown JS, Vaughan ED. Health-related quality of life after maxillectomy: a comparison between prosthetic obturation and free flap. J Oral Maxillofac Surg. 2003; 61: 174-181.
  • 175
    Gellrich NC, Schimming R, Schramm A, Schmalohr D, Bremerich A, Kugler J. Pain, function, and psychologic outcome before, during, and after intraoral tumor resection. J Oral Maxillofac Surg. 2002; 60: 772-777.
  • 176
    Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000; 8: 33-39.
  • 177
    Rose-Ped AM, Bellm LA, Epstein JB, Trotti A, Gwede C, Fuchs HJ. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs. 2002; 25: 461-467; quiz 468-469.
  • 178
    Bernier J, Domenge C, Ozsahin M, et al; European Organization for Research and Treatment of Cancer Trial,22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952.
  • 179
    Cooper JS, Pajak TF, Forastiere AA, et al; Radiation Therapy Oncology Group,9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
  • 180
    List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol. 1999; 17: 1020-1028.
  • 181
    Modi BJ, Knab B, Feldman LE, et al. Review of current treatment practices for carcinoma of the head and neck. Expert Opin Pharmacother. 2005; 6: 1143-1155.
  • 182
    Epstein JB, Wilkie DJ, Fischer DJ, Kim YO, Villines D. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009; 1: 26.
  • 183
    Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck. 2001; 23: 389-398.
  • 184
    Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck. 1999; 21: 1-11.
  • 185
    Chen SC, Liao CT, Chang JT. Orofacial pain and predictors in oral squamous cell carcinoma patients receiving treatment. Oral Oncol. 2011; 47: 131-135.
  • 186
    McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993; 20: 1493-1502.
  • 187
    Gaston-Johansson F, Franco T, Zimmerman L. Pain and psychological distress in patients undergoing autologous bone marrow transplantation. Oncol Nurs Forum. 1992; 19: 41-48.
  • 188
    von Gunten CF. Pathophysiology of pain in cancer. J Pediatr Hematol Oncol. 2011; 33( suppl 1): S12-S18.
  • 189
    Peat S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs. 2010; 16: 481-485.
  • 190
    Huskey A. Cannabinoids in cancer pain management. J Pain Palliat Care Pharmacother. 2006; 20: 43-46.
  • 191
    Newport K, Coyne P. Topical cocaine for relief of mucosal pain. J Pain Palliat Care Pharmacother. 2010; 24: 149-151.
  • 192
    Davis MP. Recent development in therapeutics for breakthrough pain. Expert Rev Neurother. 2010; 10: 757-773.
  • 193
    Gatti A, Reale C, Luzi M, et al. Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clin Drug Investig. 2010; 30( suppl 2): 39-47.
  • 194
    Bensadoun RJ, Riesenbeck D, Lockhart PB, Elting LS, Spijkervet FK, Brennan MT; Trismus Section, Oral Care Study Group, Multinational Association for Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer. 2010; 18: 1033-1038.
  • 195
    Chaudhari N, Landin AM, Roper SD. A metabotropic glutamate receptor variant functions as a taste receptor. Nat Neurosci. 2000; 3: 113-119.
  • 196
    Chandrashekar J, Hoon MA, Ryba NJ, Zuker CS. The receptors and cells for mammalian taste. Nature. 2006; 444: 288-294.
  • 197
    Scott K. Taste recognition: food for thought. Neuron. 2005; 48: 455-464.
  • 198
    Mossman K, Shatzman A, Chencharick J. Long-term effects of radiotherapy on taste and salivary function in man. Int J Radiat Oncol Biol Phys. 1982; 8: 991-997.
  • 199
    Zheng WK, Inokuchi A, Yamamoto T, Komiyama S. Taste dysfunction in irradiated patients with head and neck cancer. Fukuoka Igaku Zasshi. 2002; 93: 64-76.
  • 200
    Fernando IN, Patel T, Billingham L, et al. The effect of head and neck irradiation on taste dysfunction: a prospective study. Clin Oncol (R Coll Radiol). 1995; 7: 173-178.
  • 201
    Yamashita H, Nakagawa K, Tago M, et al. Taste dysfunction in patients receiving radiotherapy. Head Neck. 2006; 28: 508-516.
  • 202
    Comeau TB, Epstein JB, Migas C. Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer. 2001; 9: 575-580.
  • 203
    Bergdahl M, Bergdahl J. Perceived taste disturbance in adults: prevalence and association with oral and psychological factors and medication. Clin Oral Investig. 2002; 6: 145-149.
  • 204
    Tomita H, Ohtuka K. Taste disturbance after tonsillectomy. Acta Otolaryngol Suppl. 2002( 546): 164-172.
  • 205
    Kveton JF, Bartoshuk LM. The effect of unilateral chorda tympani damage on taste. Laryngoscope. 1994; 104( 1 pt 1): 25-29.
  • 206
    Landis BN, Giger R, Dulguerov P, Hugentobler M, Hummel T, Lacroix JS. Gustatory function after microlaryngoscopy. Acta Otolaryngol. 2007; 127: 1086-1090.
  • 207
    Yamashita H, Nakagawa K, Hosoi Y, et al. Umami taste dysfunction in patients receiving radiotherapy for head and neck cancer. Oral Oncol. 2009; 45: e19-e23.
  • 208
    Holscher T, Seibt A, Appold S, et al. Effects of radiotherapy on olfactory function. Radiother Oncol. 2005; 77: 157-163.
  • 209
    Ruo Redda MG, Allis S. Radiotherapy-induced taste impairment. Cancer Treat Rev. 2006; 32: 541-547.
  • 210
    Maes A, Huygh I, Weltens C, et al. De Gustibus: time scale of loss and recovery of tastes caused by radiotherapy. Radiother Oncol. 2002; 63: 195-201.
  • 211
    Mossman KL, Chencharick JD, Scheer AC, et al. Radiation-induced changes in gustatory function: comparison of effects of neutron and photon irradiation. Int J Radiat Oncol Biol Phys. 1979; 5: 521-528.
  • 212
    Shi HB, Masuda M, Umezaki T, et al. Irradiation impairment of umami taste in patients with head and neck cancer. Auris Nasus Larynx. 2004; 31: 401-406.
  • 213
    Halyard MY, Jatoi A, Sloan JA, et al. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007; 67: 1318-1322.
  • 214
    Ripamonti C, Fulfaro F. Taste alterations in cancer patients. J Pain Symptom Manage. 1998; 16: 349-351.
  • 215
    Sandow PL, Hejrat-Yazdi M, Heft MW. Taste loss and recovery following radiation therapy. J Dent Res. 2006; 85: 608-611.
  • 216
    Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2003; 57: 61-70.
  • 217
    de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Long-term quality of life of patients with head and neck cancer. Laryngoscope. 2000; 110: 98-106.
  • 218
    Oates JE, Clark JR, Read J, et al. Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2007; 133: 533-540.
  • 219
    Nelson GM. Biology of taste buds and the clinical problem of taste loss. Anat Rec. 1998; 253: 70-78.
  • 220
    Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101: 175-183.
  • 221
    Wickham RS, Rehwaldt M, Kefer C, et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum. 1999; 26: 697-706.
  • 222
    Marinone MG, Rizzoni D, Ferremi P, Rossi G, Izzi T, Brusotti C. Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients. Haematologica. 1991; 76: 519-522.
  • 223
    Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllof G, Ringden O. Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med. 1992; 21: 33-37.
  • 224
    Mott AE, Grushka M, Sessle BJ. Diagnosis and management of taste disorders and burning mouth syndrome. Dent Clin North Am. 1993; 37: 33-71.
  • 225
    Ahne G, Erras A, Hummel T, Kobal G. Assessment of gustatory function by means of tasting tablets. Laryngoscope. 2000; 110: 1396-1401.
  • 226
    Mueller C, Kallert S, Renner B, et al. Quantitative assessment of gustatory function in a clinical context using impregnated “taste strips”. Rhinology. 2003; 41: 2-6.
  • 227
    Ellegard EK, Goldsmith D, Hay KD, Stillman JA, Morton RP. Studies on the relationship between electrogustometry and sour taste perception. Auris Nasus Larynx. 2007; 34: 477-480.
  • 228
    Ikeda M, Aiba T, Ikui A, et al. Taste disorders: a survey of the examination methods and treatments used in Japan. Acta Otolaryngol. 2005; 125: 1203-1210.
  • 229
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-376.
  • 230
    Peregrin T. Improving taste sensation in patients who have undergone chemotherapy or radiation therapy. J Am Diet Assoc. 2006; 106: 1536-1540.
  • 231
    Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005; 63: 985-990.
  • 232
    Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys. 2006; 64: 684-691.
  • 233
    Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol. 2002; 12( 1 suppl 1): 4-13.
  • 234
    Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002; 52: 739-747.
  • 235
    Ripamonti C, Zecca E, Brunelli C, et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer. 1998; 82: 1938-1945.
  • 236
    Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope. 2012; 122: 813-816.
  • 237
    Ko JY, Kim MJ, Lee SG, Kho HS. Outcome predictors affecting the efficacy of clonazepam therapy for the management of burning mouth syndrome (BMS) [published online ahead of print October 29, 2011]. Arch Gerontol Geriatr.
  • 238
    Patton LL, Siegel MA, Benoliel R, De Laat A. Management of burning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103( suppl S39): e1-e13.
  • 239
    Bartoshuk LM, Snyder DJ, Grushka M, Berger AM, Duffy VB, Kveton JF. Taste damage: previously unsuspected consequences. Chem Senses. 2005; 30( suppl 1): i218-i219.
  • 240
    Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011; 22: 2086-2093.
  • 241
    Jewett A, Head C, Cacalano NA. Emerging mechanisms of immunosuppression in oral cancers. J Dent Res. 2006; 85: 1061-1073.
  • 242
    Ojha J, Islam N, Cohen DM, Marshal D, Reavis MR, Bhattacharyya I. Post-transplant lymphoproliferative disorders of oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105: 589-596.
  • 243
    Au WY, Chan EC, Pang A, et al. Nonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: incidence and molecular monitoring. Bone Marrow Transplant. 2004; 34: 981-985.
  • 244
    Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005; 105: 3802-3811.
  • 245
    Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL. Measuring comorbidity in patients with head and neck cancer. Laryngoscope. 2002; 112: 1988-1996.
  • 246
    Zeller JL. High suicide risk found for patients with head and neck cancer. JAMA. 2006; 296: 1716-1717.